Daniel E. Spratt, MD, on the Impact of Antiandrogen Treatment in Prostate Cancer: NRG Oncology/RTOG 9601 Trial
2019 ASTRO Annual Meeting
Daniel E. Spratt, MD, of the University of Michigan, discusses phase III study findings showing that 2 years of antiandrogen therapy increased cardiac and neurologic toxicities, as well as mortality from causes other than prostate cancer, in men with low levels of prostate-specific antigen after prostatectomy who received adjuvant early salvage radiotherapy (Abstract LBA1).
Sue Sun Yom, MD, PhD, of the University of California, San Francisco, discusses phase II results showing that swallowing-related quality of life after deintensified chemoradiation therapy may improve in patients with p16-positive, nonsmoking-associated, locoregionally advanced disease (Abstract LBA10).
Youssef Zeidan, MD, PhD, of the American University of Beirut Medical Center, discusses study findings showing that, in patients with one to three positive lymph nodes, postmastectomy radiation treatment decreased the risk of locoregional recurrence, particularly in estrogen receptor–positive disease (Abstract 83).
Daniel M. Trifiletti, MD, of the Mayo Clinic, discusses study findings showing that, between two different radiation doses (30 Gy/10 fractions vs 37.5 Gy/15 fractions), there was no difference in the time to cognitive failure, tumor control, or overall survival for patients with brain metastases (Abstract 19).
Erica H. Bell, PhD, of The Ohio State University, discusses phase III findings from a prognostic and predictive molecular subgroup analysis of radiotherapy vs radiotherapy plus procarbazine/lomustine/vincristine in high-risk low-grade gliomas (Abstract 161).
Alejandra Méndez Romero, MD, PhD, of Erasmus University Medical Center, discusses findings that show high local control rates with stereotactic body radiation for patients in this large published series, most of whom had colorectal cancer (Abstract 230).
